Literature DB >> 33639248

Potential and promising anticancer drugs from adenosine and its analogs.

Shuli Man1, Yingying Lu1, Lijuan Yin1, Xinkuan Cheng1, Long Ma2.   

Abstract

In recent years, many studies have shown that adenosine has efficacy for treating cancer. More importantly, some adenosine analogs have been successfully marketed to fulfill anticancer purposes. In this review, we summarize the anticancer effects of adenosine and its analogs in clinical trials and preclinical studies, with focus on their anticancer mechanisms. In addition, we link the anticancer activities of adenosine analogs with their structures through structure-activity relationship (SAR) analysis, and highlight additional promising anticancer drug candidates. We hope that this review will be of help in understanding the importance of adenosine and its analogs with anticancer activities and directing future research and development of such compounds.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33639248     DOI: 10.1016/j.drudis.2021.02.020

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  4 in total

1.  2‑Cl‑IB‑MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines.

Authors:  Jana Kotulova; Katerina Lonova; Agata Kubickova; Jana Vrbkova; Pavla Kourilova; Marian Hajduch; Petr Dzubak
Journal:  Int J Mol Med       Date:  2022-01-18       Impact factor: 4.101

Review 2.  Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?

Authors:  Jana Kotulová; Marián Hajdúch; Petr Džubák
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

3.  A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity.

Authors:  Andrea Spinaci; Michela Buccioni; Diego Dal Ben; Federica Maggi; Gabriella Marucci; Beatrice Francucci; Giorgio Santoni; Catia Lambertucci; Rosaria Volpini
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-28

Review 4.  Cyclic AMP Signaling in Biliary Proliferation: A Possible Target for Cholangiocarcinoma Treatment?

Authors:  Leonardo Baiocchi; Ilaria Lenci; Martina Milana; Lindsey Kennedy; Keisaku Sato; Wenjun Zhang; Burcin Ekser; Ludovica Ceci; Vik Meadows; Shannon Glaser; Gianfranco Alpini; Heather Francis
Journal:  Cells       Date:  2021-07-04       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.